Sellas, Life

Sellas Life Sciences: A Survival Gain, a Raised Target and a $150 Million Question

Published on 11/18/2026 at 17:03 | Editorial boerse-global.de
Maxim raised Sellas' price target to $40, keeping buy, as REGAL showed a survival benefit and the company plans a $150 million stock offering.
Sellas Life Sciences Illustration mit AI erstellt.

Maxim's decision to lift its price target on Sellas Life Sciences from $30 to $40, while keeping its buy rating, landed the same week as the company's own plan to sell $150.0 million of new stock. That pairing captures the tension running through the whole story: a genuine clinical win on one side of the ledger, a dilutive financing on the other, and a full data package still to come.

What REGAL actually showed

The trial in question is REGAL, a randomized, open-label Phase 3 study of Galinpepimut-S — GPS for short — as a maintenance therapy in acute myeloid leukemia. It enrolled 126 patients, all in second or later remission and all ineligible for an allogeneic stem cell transplant. The comparator was the investigator's choice of best available treatment, which places the findings firmly within a narrow, post-salvage population rather than the broader AML universe.

On the primary endpoint of overall survival, GPS delivered a median of 24.0 months against 14.7 months for the control arm. Sellas put the reduction in risk of death at 41%, with a hazard ratio of 0.59 and a two-sided p-value of 0.035 — enough, by the company's account, to clear the bar of statistical significance.

That the endpoint was overall survival matters in its own right. A promising immune response in the lab and a demonstrated survival advantage are not the same claim, and REGAL tested the latter. The vaccine is designed to provoke an immune attack on WT1, a target present in most AML cases, and it does so without personalization — a synthetic peptide approach that contrasts with the individualized melanoma vaccine Merck and Moderna took through a prior Phase 3 success. BioCentury read the REGAL result as evidence that cancer vaccines are gaining traction in relapse prevention, though the two programs address different diseases and different treatment settings. A win for one candidate is not a class-wide proof of efficacy.

Should investors sell immediately? Or is it worth buying Sellas Life Sciences?

Safety looked manageable. Sellas reported no new safety signals, with adverse events mostly mild to moderate and dominated by local reactions at the injection site.

The parts still missing

What investors do not yet have is the complete picture. Analysis of secondary endpoints is ongoing, and a peer-reviewed publication has not appeared. Israel Stern, an analyst at GlobalData, framed the achievement for Clinical Trials Arena around the hurdle that matters most: GPS has now shown a survival benefit in a blood cancer vaccine.

Regulatory work is at the planning stage. Sellas has held discussions with the FDA on its approval strategy and is preparing a BLA submission for the first half of 2027, aiming for an accelerated pathway. A planned filing, plainly, is not an approval.

Financing enters the frame

Then there is the capital raise. Sellas announced a public underwritten offering of $150.0 million, with a 30-day option granting the underwriters up to $22.5 million in additional shares. All shares on offer come from the company. J.P. Morgan and TD Cowen are joint bookrunners. Closing, timing and final terms depend on market conditions and other conditions, so the placement should not be treated as done.

Until the final price and share count are set, existing holders cannot put a number on the dilution ahead of them. The stock's -11% move today sits inside this financing window, even as Maxim turns more constructive on the name.

Two separate questions therefore frame the investment case. What will the full REGAL analyses add, and on what terms will the share sale clear? The survival benefit, the planned BLA and the unresolved financing each deserve their own yardstick — and a higher target price settles none of them.

Ad

Sellas Life Sciences Stock: New Analysis - 18 November

Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Sellas Life Sciences analysis...

Disclaimer...
en | US81642T2096 | SELLAS | boerse | 70531624 |